Five Prime Therapeutics Inc (FPRX) 24.79 $FPRX
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BIIB: 475.98 (+42.33), GLMD: 13.25 (+1.60), HIIQ: 9.13 (-0.11), VTAE: 12.36 (+1.70), CLDN: 26.28 (-0.98), ATRA: 38.78 (+2.89), VBLT: 5.75 (+1.01), CORT: 5.60 (-0.25), FPRX: 24.79 (-1.18)
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
GlobeNewswire - Thu Mar 19, 12:30PM CDT
Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to utilize Vaccinex's ActivMAb(R) antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime's proprietary discovery platform.
FPRX: 24.79 (-1.18)
Five Prime ups revenues 39% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:08AM CDT
FPRX: 24.79 (-1.18)
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:25PM CDT
FPRX: 24.79 (-1.18)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 4:38PM CDT
WIX: 18.96 (-0.04), OLED: 44.42 (+0.11), FRSH: 16.49 (+0.02), ANTH: 4.34 (-0.08), AKRX: 49.03 (-0.41), RTRX: 22.34 (+0.17), RSPP: 25.79 (+0.34), TUES: 16.59 (+0.14), ADBE: 77.36 (+0.22), FPRX: 24.79 (-1.18)
Five Prime Therapeutics posts 4Q loss
Automated Insights - Tue Mar 17, 3:46PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $11.8 million in its fourth quarter.
FPRX: 24.79 (-1.18)
Five Prime Therapeutics misses by $0.45, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:07PM CDT
FPRX: 24.79 (-1.18)
Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 17
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2014 financial results on Tuesday, March 17, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Present at the RBC Capital Markets 2015 Healthcare Conference
GlobeNewswire - Wed Feb 18, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25, 2015 at 10:30 AM Eastern Standard Time. The conference will take place at the New York Palace Hotel in New York City.
FPRX: 24.79 (-1.18)
Has Pfizer Inc. Finally Solved Its Immuno-oncology Problem?
George Budwell, The Motley Fool - Motley Fool - Wed Feb 18, 9:04AM CST
Despite its humble beginnings and numerous setbacks, immunotherapy is on the cusp of becoming a standard part of cancer care, right alongside chemotherapy and surgery. According to some experts, this new class of treatments could generate somewhere...
MRK: 58.58 (+0.37), AZN: 72.70 (+1.80), PFE: 34.25 (+0.10), BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
FPRX: 24.79 (-1.18)
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Feb 04, 10:59AM CST
Bristol-Myers Squibb 's dramatic reorganization effort, following the loss of patent protection for several top-selling drugs, appears to be hitting an inflection point. Although total revenue was down by 3% in 2014, to $15.9 billion, the...
PFE: 34.25 (+0.10), AZN: 72.70 (+1.80), BMY: 67.76 (-0.56), NVS: 101.68 (+1.81), FPRX: 24.79 (-1.18), CELG: 128.50 (+3.17)
Insider Buys And Sells: A. M. Castle, Microsoft
Asif Suria - at Seeking Alpha - Sun Feb 01, 10:57AM CST
Welcome to edition 241 of Insider Weekends. Insider buying increased significantly last week with insiders buying $196.76 million of stock compared to $16.43 million in the week prior. Selling also increased with insiders selling $1.49 billion of...
RF: 9.64 (+0.14), EA: 57.28 (+1.32), LGF: 33.66 (-0.47), CAS: 3.64 (+0.11), TWTR: 48.44 (+0.51), MSFT: 42.88 (+0.60), TCBI: 49.54 (+0.91), SCHW: 30.01 (+0.59), FPRX: 24.79 (-1.18)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 56.51 (+0.80), CSWC: 48.76 (+0.80), FCS: 19.13 (+0.25), MLNK: 3.74 (-0.01), ADBE: 77.36 (+0.22), VSAR: 20.35 (+0.36), LCI: 68.57 (-0.32), WIW: 11.27 (+0.01), QRVO: 80.80 (+0.42), PSEM: 16.07 (+0.44), OPK: 14.52 (-0.15), CUDA: 38.33 (-1.64), BGG: 19.83 (+0.22), RWC: 6.00 (-0.08), PE: 14.84 (+0.24), MSFT: 42.88 (+0.60), BK: 40.57 (+0.27), FPRX: 24.79 (-1.18), INFN: 19.12 (+0.03)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 475.98 (+42.33), PSTI: 2.80 (-0.05), ASPX: 79.99 (-6.73), LPTN: 3.46 (-0.21), IBIO: 0.79 (+0.02), FGEN: 30.93 (+1.52), AQXP: 10.82 (-0.45), ITMN: 73.89 (-0.02), GALT: 3.86 (-0.03), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), GILD: 102.29 (+0.85), CGEN: 7.61 (-0.22), FPRX: 24.79 (-1.18), CELGZ: 3.05 (+0.02)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 54.57 (-1.36), ALXN: 187.71 (-1.36), ILMN: 196.02 (-3.79), FPRX: 24.79 (-1.18)
5 Stocks Insiders Love Right Now: eHealth, Worthington Industries and More
at The Street - Wed Jan 21, 6:00AM CST
Insiders at these comapnies have been snapping up shares of their own stocks lately.
OVAS: 46.97 (+1.98), CDNA: 5.65 (-0.37), WOR: 27.90 (+0.88), FPRX: 24.79 (-1.18), EHTH: 10.24 (+0.06)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.58 (+0.37), EXAS: 24.18 (-0.20), BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BIIB: 475.98 (+42.33), GLMD: 13.25 (+1.60), HIIQ: 9.13 (-0.11), VTAE: 12.36 (+1.70), CLDN: 26.28 (-0.98), ATRA: 38.78 (+2.89), VBLT: 5.75 (+1.01), CORT: 5.60 (-0.25), FPRX: 24.79 (-1.18)
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
GlobeNewswire - Thu Mar 19, 12:30PM CDT
Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to utilize Vaccinex's ActivMAb(R) antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime's proprietary discovery platform.
FPRX: 24.79 (-1.18)
Five Prime ups revenues 39% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:08AM CDT
FPRX: 24.79 (-1.18)
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:25PM CDT
FPRX: 24.79 (-1.18)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 4:38PM CDT
WIX: 18.96 (-0.04), OLED: 44.42 (+0.11), FRSH: 16.49 (+0.02), ANTH: 4.34 (-0.08), AKRX: 49.03 (-0.41), RTRX: 22.34 (+0.17), RSPP: 25.79 (+0.34), TUES: 16.59 (+0.14), ADBE: 77.36 (+0.22), FPRX: 24.79 (-1.18)
Five Prime Therapeutics posts 4Q loss
Automated Insights - Tue Mar 17, 3:46PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $11.8 million in its fourth quarter.
FPRX: 24.79 (-1.18)
Five Prime Therapeutics misses by $0.45, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:07PM CDT
FPRX: 24.79 (-1.18)
Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 17
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2014 financial results on Tuesday, March 17, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Present at the RBC Capital Markets 2015 Healthcare Conference
GlobeNewswire - Wed Feb 18, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25, 2015 at 10:30 AM Eastern Standard Time. The conference will take place at the New York Palace Hotel in New York City.
FPRX: 24.79 (-1.18)
Has Pfizer Inc. Finally Solved Its Immuno-oncology Problem?
George Budwell, The Motley Fool - Motley Fool - Wed Feb 18, 9:04AM CST
Despite its humble beginnings and numerous setbacks, immunotherapy is on the cusp of becoming a standard part of cancer care, right alongside chemotherapy and surgery. According to some experts, this new class of treatments could generate somewhere...
MRK: 58.58 (+0.37), AZN: 72.70 (+1.80), PFE: 34.25 (+0.10), BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
Five Prime Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 3:06PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
FPRX: 24.79 (-1.18)
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Feb 04, 10:59AM CST
Bristol-Myers Squibb 's dramatic reorganization effort, following the loss of patent protection for several top-selling drugs, appears to be hitting an inflection point. Although total revenue was down by 3% in 2014, to $15.9 billion, the...
PFE: 34.25 (+0.10), AZN: 72.70 (+1.80), BMY: 67.76 (-0.56), NVS: 101.68 (+1.81), FPRX: 24.79 (-1.18), CELG: 128.50 (+3.17)
Insider Buys And Sells: A. M. Castle, Microsoft
Asif Suria - at Seeking Alpha - Sun Feb 01, 10:57AM CST
Welcome to edition 241 of Insider Weekends. Insider buying increased significantly last week with insiders buying $196.76 million of stock compared to $16.43 million in the week prior. Selling also increased with insiders selling $1.49 billion of...
RF: 9.64 (+0.14), EA: 57.28 (+1.32), LGF: 33.66 (-0.47), CAS: 3.64 (+0.11), TWTR: 48.44 (+0.51), MSFT: 42.88 (+0.60), TCBI: 49.54 (+0.91), SCHW: 30.01 (+0.59), FPRX: 24.79 (-1.18)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 56.51 (+0.80), CSWC: 48.76 (+0.80), FCS: 19.13 (+0.25), MLNK: 3.74 (-0.01), ADBE: 77.36 (+0.22), VSAR: 20.35 (+0.36), LCI: 68.57 (-0.32), WIW: 11.27 (+0.01), QRVO: 80.80 (+0.42), PSEM: 16.07 (+0.44), OPK: 14.52 (-0.15), CUDA: 38.33 (-1.64), BGG: 19.83 (+0.22), RWC: 6.00 (-0.08), PE: 14.84 (+0.24), MSFT: 42.88 (+0.60), BK: 40.57 (+0.27), FPRX: 24.79 (-1.18), INFN: 19.12 (+0.03)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 475.98 (+42.33), PSTI: 2.80 (-0.05), ASPX: 79.99 (-6.73), LPTN: 3.46 (-0.21), IBIO: 0.79 (+0.02), FGEN: 30.93 (+1.52), AQXP: 10.82 (-0.45), ITMN: 73.89 (-0.02), GALT: 3.86 (-0.03), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56), GSK: 48.81 (+0.60), GILD: 102.29 (+0.85), CGEN: 7.61 (-0.22), FPRX: 24.79 (-1.18), CELGZ: 3.05 (+0.02)
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:50PM CST
Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
NLNK: 54.57 (-1.36), ALXN: 187.71 (-1.36), ILMN: 196.02 (-3.79), FPRX: 24.79 (-1.18)
5 Stocks Insiders Love Right Now: eHealth, Worthington Industries and More
at The Street - Wed Jan 21, 6:00AM CST
Insiders at these comapnies have been snapping up shares of their own stocks lately.
OVAS: 46.97 (+1.98), CDNA: 5.65 (-0.37), WOR: 27.90 (+0.88), FPRX: 24.79 (-1.18), EHTH: 10.24 (+0.06)
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 18, 8:12AM CST
Source: Flickr user Eric Norris Cancer of any type is a terrifying disease to fight. There are simply so many unknowns associated with cancer, such as why it occurs in one person and not the next and what triggers its growth in the first place. ...
MRK: 58.58 (+0.37), EXAS: 24.18 (-0.20), BMY: 67.76 (-0.56), FPRX: 24.79 (-1.18)
